AllerFund I

AllerFund Ventures, established in 2020 and based in Scarsdale, New York, is a venture capital firm focused on creating social impact for the food allergy community. The firm aims to accelerate the development and commercialization of innovative treatments, diagnostics, and products for individuals with food allergies, particularly children and those at risk. AllerFund invests in early-stage companies across various sectors, including biopharma, medical devices, diagnostics, and consumer products, with the goal of facilitating breakthroughs that can lead to cures and significantly enhance the quality of life for affected individuals.

Lisa Shapiro Strovink

Managing Partner

7 past transactions

Amulet

Series A in 2024
Amulet focuses on enhancing food safety by addressing hidden threats in the food system through its two primary brands. Allergy Amulet serves consumers by providing a portable electrochemical detection system that identifies potentially life-threatening allergenic ingredients in food. This wearable device alerts users to allergens, ensuring informed dietary choices. Amulet Scientific targets businesses and manufacturers, offering a detection platform that helps identify various molecular targets, including food toxins and environmental contaminants. This dual approach enables both consumers and food producers to effectively manage safety risks in the food supply chain.

ATANIS

Venture Round in 2023
ATANIS Biotech is a biotechnology company focused on advancing clinical allergy research and developing diagnostic assays. The company aims to enhance and streamline the current standards of allergy diagnosis through a novel functional cell-based assay. This innovative approach not only simplifies the diagnostic process but also predicts the effectiveness of various treatments. By providing a reliable tool for functional allergy screening, ATANIS Biotech supports healthcare providers and patients in managing allergies more effectively.

IgGenix

Series B in 2023
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Alladapt Immunotherapeutics

Venture Round in 2022
Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

IgGenix

Series A in 2021
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Bryn Pharma

Venture Round in 2021
Bryn Pharma LLC is a biotechnology company based in Raleigh, North Carolina, that focuses on developing a bi-dose intranasal device for the emergency treatment of anaphylaxis. This innovative product offers a needle-free solution for administering epinephrine, serving as a convenient alternative to traditional auto-injectors. Designed for ease of use, the device allows patients to manage allergic reactions and anaphylactic episodes without requiring special medical training. Its compact and portable design makes it practical for individuals to carry, ensuring they have access to emergency treatment when needed. Founded in 2017, Bryn Pharma was previously known as Epi-Now, LLC.

Allergy Amulet

Seed Round in 2020
Allergy Amulet Inc., founded in 2016 and based in Madison, Wisconsin, specializes in the manufacture and sale of consumer food allergen sensors designed to test for common allergens in food. The Allergy Amulet device is recognized as the world's smallest and fastest food allergen sensor, providing results in seconds. Its portable design allows users to carry it on a keychain, necklace, or wristband, making it convenient for families, individuals, and businesses. With food allergies affecting approximately 32 million Americans and hundreds of millions globally, Allergy Amulet aims to enhance the quality of life for those with food allergies and intolerances, enabling them to enjoy their meals with greater safety and confidence.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.